US OptionsDetailed Quotes
BGNE240816C120000
- 35.60
- 0.000.00%
15min DelayClose Jul 23 15:59 ET
0.00High0.00Low
35.60Open35.60Pre Close0 Volume3 Open Interest120.00Strike Price0.00Turnover36.41%IV-1.23%PremiumAug 16, 2024Expiry Date37.53Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9986Delta0.0003Gamma4.15Leverage Ratio-0.0184Theta0.0790Rho4.14Eff Leverage0.0019Vega
BeiGene Stock Discussion
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24 (sBLA)
$BeiGene(BGNE.US)$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas (1L)
‣ PDUFA: July 2024 (sBLA)
$Phathom Pharmaceuticals(PHAT.US)$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA: 7/19/24 (NDA)
$AstraZeneca(AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24(sBLA)
$BeiGene(BGNE.US)$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas
‣ PDUFA: July 2024 (BLA)
$Arcutis Biotherapeutics(ARQT.US)$ : pending decision 🤔
⇨ ARQ-151 topical roflumilast cream
‣ Atopic Dermatitis (aged 6 & older children)
‣ PDUFA date: 7/7/24 (sNDA)
Upcoming PDUFAs & AdCom in July: 📅👇
$Phathom Pharmaceuticals(PHAT.US)$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA date: 7/19/24 (NDA)
$AstraZeneca(AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom date: 7/25/24(sBLA)
$BeiGene(BGNE.US)$ :...
$Arcutis Biotherapeutics(ARQT.US)$ : ARQ-151 topical roflumilast cream
$Phathom Pharmaceuticals(PHAT.US)$ : VOQUEZNA® (vonoprazan)
$AstraZeneca(AZN.US)$ : Imfinzi + chemotherapy - AdCom
$BeiGene(BGNE.US)$ : TEVIMBRA (tislelizumab)
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US)$
$BeiGene(BGNE.US)$
$ACADIA Pharmaceuticals(ACAD.US)$
$Madrigal Pharmaceuticals(MDGL.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Revolution Medicines(RVMD.US)$
$Kymera Therapeutics(KYMR.US)$
$AbCellera Biologics(ABCL.US)$
$Bicycle Therapeutics(BCYC.US)$
$Edgewise Therapeutics(EWTX.US)$
$Immunocore(IMCR.US)$
$Kodiak Sciences(KOD.US)$
$Roivant Sciences(ROIV.US)$
...
$BeiGene(BGNE.US)$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US)$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US)$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US)$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
$Eyenovia(EYEN.US)$ $Vanda Pharmaceuticals(VNDA.US)$ $Mirum Pharmaceuticals(MIRM.US)$ $Madrigal Pharmaceuticals(MDGL.US)$ $Geron(GERN.US)$ $Bristol-Myers Squibb(BMY.US)$ $2seventy bio(TSVT.US)$ $Legend Biotech(LEGN.US)$ $OptiNose(OPTN.US)$ $Orchard Therapeutics(ORTX.US)$ $Merck & Co(MRK.US)$ $Akebia Therapeutics(AKBA.US)$ $AstraZeneca(AZN.US)$ $Liquidia(LQDA.US)$ $Esperion Therapeutics(ESPR.US)$ $Regeneron Pharmaceuticals(REGN.US)$ $BeiGene(BGNE.US)$
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
alphaedgeinvest...
$BEIGENE(06160.HK)$ $BeiGene(BGNE.US)$
No comment yet